Meeting
2022 ASCO Annual Meeting
Association between immune-related adverse events and microbiome composition in patients with advanced non–small cell lung cancer treated with immunotherapy.
Authors
Marion Tonneau
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
Marion Tonneau , Corentin Richard , Alexis Nolin-Lapalme , Edouard Auclin , Myriam Benlaifaoui , Mayra Ponce , Afnan Al-Saleh , Normand Blais , Marie Florescu , Mustapha Tehfe , Julie Malo , Meriem Messaoudene , Yusuke Okuma , Taiki Hakozaki , Bertrand Routy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9036)
DOI
10.1200/JCO.2022.40.16_suppl.9036
Abstract #
9036
Poster Bd #
24
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
First Author: Taiki Hakozaki
Poster
2023 ASCO Annual Meeting
Association between duration of immunotherapy and overall survival in advanced non–small-cell lung cancer.
First Author: Lova Sun
Poster
2020 ASCO Virtual Scientific Program
Physiologic colonic uptake of 18F-FDG on PET/CT predicts immunotherapy response and gut microbiome diversity in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Lena Cvetkovic
Poster
2020 ASCO Virtual Scientific Program
Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer.
First Author: R. Brian Mitchell